Researchers at Rice University have developed a low-cost method to attach thiophosphate molecules to biological compounds, addressing a longstanding cost barrier in pharmaceutical manufacturing. According to chemistry professor Hans Renata, cellular dephosphorylation normally strips phosphate groups from drug structures during processing, but thiophosphate acts as a resilient analog that prevents this breakdown.
The Phosphate Switch Dilemma in Drug Development
Cells regularly use phosphate as a chemical switch to regulate molecular functions through phosphorylation and dephosphorylation. While this cellular process is essential for human biology, it creates major hurdles for drug designers. Therapeutics built on biological compounds often feature phosphate structures that the body quickly dephosphorylates, which severely reduces overall drug efficacy, as noted by Hans Renata.
To prevent this degradation, scientists utilize thiophosphate, a specialized analog that mimics regular phosphate while resisting cellular removal. However, the traditional reagents required to add thiophosphate have remained prohibitively expensive for large-scale production. According to postdoctoral fellow and co-first author Xiangyu Wu, the standard reagent known as ATPγS is exceptionally costly, limiting its use to tiny experimental amounts.
Adapting ATP Recycling for Thiophosphate
The research team overcame the high cost of ATPγS by adapting established ATP recycling methods for use with the thiophosphate analog. While standard ATP molecules can be continuously reused in phosphorylation reactions through specific enzymes and sacrificial donors, ATPγS was previously thought to be single-use. Graduate student and co-first author Yu Fu explained that testing whether the recycling process could adapt to ATPγS proved successful when paired with the correct enzymes and donor molecules.
Did you know? Phosphorylation acts like an on/off switch inside human cells, adding and removing phosphate groups to control various molecular functions on demand.
This newly adapted recycling method requires only small quantities of ATPγS to modify numerous chemical compounds. The technique offers high flexibility, allowing researchers to attach thiophosphates to different chemical structures and specific targeted locations across various molecular classes.
Implications for Antisense Oligonucleotides
The cost-reduction method opens up manufacturing pathways for complex therapeutics, including antisense oligonucleotides used to treat genetic diseases. These specialized drugs rely heavily on phosphate structures. According to Hans Renata, preliminary results indicate the recycling method could provide a more efficient and economical production route for these treatments.
Funding for the research was provided by the American Chemical Society Green Chemistry Institute Pharmaceutical Roundtable research grant, the Welch Foundation under grant C2159, and the Cancer Prevention and Research Institute of Texas under grant RR220087.
Frequently Asked Questions
What is the main challenge with phosphate-based drugs?
Cells naturally dephosphorylate drug structures as the body processes them, which significantly reduces the medication’s overall efficacy.
Why is thiophosphate difficult to use in manufacturing?
According to the Rice University research team, adding thiophosphate traditionally requires ATPγS, an exceptionally expensive molecule that makes large-scale reactions cost-prohibitive.
How does the new recycling method work?
Researchers adapted standard ATP recycling techniques by combining the right enzymes and sacrificial donor molecules, allowing a small amount of ATPγS to be reused across numerous chemical reactions.
Explore More Research Updates
Subscribe to our newsletter to receive the latest scientific breakthroughs, pharmaceutical innovations, and laboratory discoveries directly in your inbox.
Keep reading